TICKERNERD
Menu
MISTMISTHealthcare · Biotechnology

MIST Stock Forecast: Milestone Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.71
−5.93% on the day

The 7 Wall Street analysts covering Milestone Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +883.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$94.2M
Ticker Nerd rank
16 / 100
Median analyst target
$7.00
Analysts covering
7
Revenue$559K
Operating income−$25.6M
Net income−$28.6M
Free cash flow−$22.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.7%
1M
−36.7%
YTD
−64.7%
1Y
−64.4%
From 52W high
−75.9%
From 52W low
0.0%
$0.71
$2.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Milestone Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
76
Accruals
52
Revisions
46
Quality
41
Growth
31
Volatility
27
Value
21
Momentum
10
Issuance
4

Size (76): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MIST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26MISTHigh $8.00Median $7.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $2.00Median $7.00High $8.00

The green dot is the last close — the median target sits +883.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$8.00
20 Aug 2026Cantor FitzgeraldInitiatesOverweight$3.00
20 Aug 2026Cantor FitzgeraldInitiatesOverweight—
14 May 2026Wells FargoMaintainsOverweight$8.00 → $7.00
14 May 2026Wells FargoMaintainsOverweight—
6 Jan 2026HC Wainwright & Co.ReiteratesBuy—
16 Dec 2025Wells FargoMaintainsOverweight—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
15 Dec 2025TD CowenUpgradeBuy—
11 Sept 2025Wells FargoInitiatesOverweight—
5 June 2025HC Wainwright & Co.AssumesBuy$5.00
1 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Oct 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—
1 July 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MIST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Milestone Pharmaceuticals, Inc. returned −64.4% against +16.2% for the S&P 500, dividends included.

MIST vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140160Jan 26Apr 26Jul 26Oct 26MISTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Milestone Pharmaceuticals, Inc. (MIST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
38.3×

Cheaper than 6% of US stocks

Price / book
5.6×

Cheaper than 18% of US stocks

EV / EBITDA
−1.0×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
134.9%

Higher than 94% of US stocks

Earnings growth (YoY)
—
Gross margin
94.3%

Higher than 98% of US stocks

Operating margin
−4585.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−35522.6%

Higher than 1% of US stocks

Return on assets
−42.8%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Milestone Pharmaceuticals, Inc. (MIST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Milestone Pharmaceuticals, Inc. has a market value of $94.2M and an enterprise value of $77.9M.

  • Revenue in the twelve months to 30 June 2026: $2.3M. The latest quarter grew 134.9% year on year.

  • Net income over the same four quarters: −$84.0M, a −3585.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$61.6M.

  • Shares outstanding: 124.5M.

  • Trailing P/E: −1.0×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Milestone Pharmaceuticals, Inc. employs 38 people — $62K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

MIST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MISTMilestone Pharmaceuticals, Inc.$94.2M
16
ICCCImmuCell Corp.$88.2M
93
RLYBRallybio Corp.$89.7M
55
NMRANeumora Therapeutics, Inc.$87.3M
30
EQEquillium, Inc.$91.0M
37
CGTXCognition Therapeutics, Inc.$85.1M
35
ATRAAtara Biotherapeutics, Inc.$92.6M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Milestone Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIST news & analysis

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

GlobeNewsWire · 24 Sept 2026positive

Milestone Pharmaceuticals announced that the Montreal Heart Institute, its first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial, has enrolled its first patient. The trial evaluates etripamil nasal spray as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Why it matters — The enrollment of the first Canadian patient marks continued progress in patient recruitment for Milestone's pivotal Phase 3 trial evaluating etripamil, a key pipeline candidate for AFib-RVR.

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

GlobeNewsWire · 3 Sept 2026positive

Milestone Pharmaceuticals announced that the National Medical Products Administration (NMPA) in China approved etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), marking the first regulatory approval of etripamil outside the United States. Everest Medicines will lead commercialization in Greater China, targeting an estimated 3-6 million Chinese patients with PSVT.

Why it matters — This represents a significant international regulatory milestone for Milestone's lead product candidate, expanding its commercial reach beyond the United States through a partnering arrangement in the Chinese market.

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Milestone Pharmaceuticals announced that its management will present at, and participate in, several upcoming investor conferences. The announcement was made by the biopharmaceutical company, which focuses on developing and commercializing innovative cardiovascular medicines.

Why it matters — MIST watchers would care because these conference presentations offer management an opportunity to update investors on the company's cardiovascular medicine pipeline and strategy.

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes

GlobeNewsWire · 27 Aug 2026neutral

Milestone Pharmaceuticals announced that findings from a longitudinal study on how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives and quality of life between episodes were presented at ESC Congress 2026. The data describe the disease burden patients experience during periods between episodes.

Why it matters — The presentation provides insight into the patient burden of PSVT, which is relevant context for Milestone's cardiovascular development efforts.

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

GlobeNewsWire · 21 Aug 2026positive

Milestone Pharmaceuticals announced the initiation of its pivotal Phase 3 trial (ReVeRA-301) of etripamil nasal spray for the self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is evaluating the same 70 mg repeat-dose regimen that is FDA approved for paroxysmal supraventricular tachycardia (PSVT).

Why it matters — This advances a new, potentially significant indication for etripamil beyond its approved PSVT use, expanding Milestone's pipeline and commercial opportunity.

FAQ

Frequently asked questions about MIST stock

What is the MIST stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Milestone Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIST stock a buy right now?

Of the 7 analysts covering Milestone Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Milestone Pharmaceuticals, Inc. 16 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIST?

As at 8 Oct 2026, Milestone Pharmaceuticals, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (76 of 100).

Will MIST stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +883.0% from the last close, and Ticker Nerd's factor model ranks Milestone Pharmaceuticals, Inc. 16 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIST stock forecast for 2030?

No analyst covering Milestone Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has MIST stock performed over the past year?

Milestone Pharmaceuticals, Inc. returned -64.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Milestone Pharmaceuticals, Inc. do?

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults.

What is the latest news on MIST?

The most recent item we track (GlobeNewsWire, 24 Sept 2026): "Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR". Milestone Pharmaceuticals announced that the Montreal Heart Institute, its first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial, has enrolled its first patient. The trial evaluates etripamil nasal spray as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Company

About Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate. The company centers its work on self-administered therapies that can be used outside the emergency department, addressing episodic heart rhythm conditions through a nasal spray delivery format. Based in Montreal, Canada, Milestone Pharmaceuticals Inc. serves the cardiovascular and biotechnology markets through its current product portfolio and ongoing clinical and commercial activities in the United States and Canada.

CEO Mr. Joseph G. Oliveto M.B.A. · 38 employees · Canada · https://www.milestonepharma.com